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351 Management dilemmas of renal calculi in cystic ﬁbrosis
F. Healy1, M. Waldron2, F. Quinn2, G. Canny1. 1Cystic Fibrosis Unit, Our Lady’s
Children’s Hospital, Dublin, Ireland; 2Nephrourology Department, Our Lady’s
Children’s Hospital, Dublin, Ireland
Aims: We assessed the investigation and treatment of nephrolithiasis in our
paediatric CF populaton.
Methods: Cases were identiﬁed by chart review.
Results: 3 of 150 patients had renal calculi and were referred to the nephrology
clinic.
The ﬁrst case was an incidental ﬁnding of bilateral nephrocalcinosis in a 1 year
old. 24 hour urinary calcium: creatine, oxalate:creatinine and serum urate level
were normal. While the patient remains asymptomatic, annual ultrasound is the
only intervention.
In the second case, a single renal calculus was discovered in a 12 year old.
Urinary calcium:creatinine was elevated on 2 occasions. Urinary urate and oxalate
ratios were normal. This calculus possibly developed while the patient was mildly
dehydrated and on high dose vitamin C. Lithotripsy was discussed as a non urgent
treatment option.
The third case was a 3 year old with bilateral calculi. Serum urate, oxalate and
urine calcium:creatinine levels were normal. 24 hour urinary oxalate:creatinine was
elevated on 1 occasion.
2 lithotripsy attempts were unsuccessful. A trial of cholestyramine and probiotics
was given and vitamin preparations were altered to minimise vitamin C and
maximise vitamin A and D intake. Oral Oxalobacter formigenes as a probiotic
and oral vitamin B6 were considered.
The patient remains asymptomatic but on ultrasound calculi size is increasing with
ongoing risk of obstruction. Treatment options of percutaneous nephrolithotomy,
transurethral lithoplasty or an open procedure are being considered for this chal-
lenging case.
Conclusion: Many factors should be considered in calculi formation in CF. Treat-
ment options include dietary modiﬁcations and supplements. However, ultimately
laser or surgical therapies may have to be considered.
352* Renal impairment in the adult cystic ﬁbrosis population
S.J. King1,2, C. De Clercq1, D.J. Topliss1, N. Thomson1, J.W. Wilson1. 1CF
Service, Alfred Hospital, Melbourne, VIC, Australia; 2Nutrition and Dietetics Unit,
Monash University, Melbourne, VIC, Australia
Surveillance to identify complications associated with longevity in CF, including
renal disease, is important. Diabetic nephropathy has been observed in the absence
of CFRD, suggesting a need for screening for renal impairment. This study aimed
to assess renal function in a sample of adults with CF.
Methods: Adults with CF aged 25 years or over (n = 29, mean age 36.7±9.1 years)
were studied. 15 patients (9 males) had CFRD, and 14 (10 males) had no history
of CFRD. 24 hour urine collections were analysed for UrCrCl. Renal impairment
was deﬁned as <90ml/min. Serum creatinine level was used to calculate eGFR
(MDRD formula). eGFR was classiﬁed as normal/mildly impaired (>60ml/min),
or impaired (<60ml/min). Sensitivity of eGFR for identifying impaired UrCrCl
was calculated. Data were collected on usage of intravenous tobramycin and peak
serum tobramycin levels over the previous 2 years. Mann-Whitney and unpaired
t-tests were used to compare variables.
Results: Mean UrCrCl was 105±35ml/min. 8 patients (27.6%) had renal impair-
ment. The sensitivity of eGFR for identifying impaired UrCrCl was 38%. 5 of the
8 patients with impaired UrCrCl had CFRD. UrCrCl was similar in CFRD and non-
CFRD patients (98±77 vs 112±33ml/min, p = 0.29). Age, gender, FEV1%predicted
and HbA1c level did not correlate with UrCrCl. The median proportion of peak
serum tobramycin levels >15mg/L was similar in impaired and normal renal
function groups (29% vs 33%, p = 0.83).
Conclusion: Renal impairment is common in the adult CF population and is not
conﬁned to patients with CFRD. Screening using eGFR is a poor predictor of
impaired UrCrCl. Surveillance to monitor renal function is indicated in adults
with CF. Determination of UrCrCl should be included in the screening process.
353* Testosterone deﬁciency in adult males with cystic ﬁbrosis
M.F. Katz1, C. Wheeler1, S. Cumming1. 1Baylor College of Medicine, Houston,
TX, USA
Background: The median survival of individuals with cystic ﬁbrosis has climbed
to 36.8 years. This has allowed recognition of medical complications associated
with CF. Body weight has prognostic value and the integrity of bone mineral density
(BMD) and muscle mass is important for long term health. Sex steroid deﬁciency
results from secondary hypogonadism and likely contributes to CF-related bone
disease, however no consistent association has been seen. Rossini et al. (Bone
2004) found signiﬁcantly lower free testosterone (T) levels in CF men with vertebral
fractures. Leifke Eur J Endocrine 2003 found that 11 out of 40 CF patients had
serum testosterone levels 2 sd. below the mean of normal. The exact prevalence of
low total T levels in an adult CF population is not known. Features of hypogonadism
in CF males are low T and low/normal LH. Low T levels are related to chronic
inﬂammation, stress, medication and perhaps CFTR dysfunction.
Methods: 52 male adult patients from a single adult CF Center were tested for T
levels between May 2006 and July 2007. 20/52 (38%) patients underwent DEXA
scanning to determine BMD of hip and spine and t-scores were recorded. Patient
characteristics: Mean age 32± 7 years; weight, kg 70±13; BMI, kg/m2 22.85±3;
FEV1% predicted 0.48±0.26; 12/52 homozygous F508.
Results: 24/52 (46%) of patients had total serum testosterone levels <400 ng/dL.
12/52 (24%) of patients had total serum testosterone levels <250 ng/dL. Scattergram
analysis of testosterone levels in relation to BMI and t-scores of spine and hip
revealed no signiﬁcant correlation.
Conclusions: In this observational study, there was low T levels in 23% of patients.
There was no direct correlation between serum testosterone levels and bone mineral
density. Further co-morbidities will be investigated.
354* Pilot study on the effects of lycopene on oxidation and
fatty acids in CF patients
G. Wojewodka1, F. Kopriva2, I. Oborna2, J.B. De Sanctis3, M. Hadjuch2,
D. Radzioch1. 1Human Genetics, McGill University, Montreal, QC, Canada;
2Medicine, Palacky University in Olomouc, Olomouc, Czech Republic; 3Institute
of Immunology, Central University of Venezuela, Caracas, Venezuela
Cystic ﬁbrosis (CF) patients have an imbalance in fatty acids: increased arachidonic
acid (AA) and decreased docosahexaenoic acid (DHA). We recently reported that
CF patients and CF mice have a deﬁciency in another phospholipid class, ceramides,
which was normalized in CF mice after treatment with fenretinide, a semi-synthetic
retinoic anti-oxidant. A pilot study using CF patients was designed to assess if
lycopene, a natural anti-oxidative retinoid, might also induce a similar improvement.
Three CF patients with severe imbalances compared to healthy controls (HC; n = 90)
were selected for lycopene treatment. CF patients took 20mg (10mg twice a day)
of lycopene for 3 months. Blood samples were taken prior to treatment, after 1 and
3 months of treatment. Ceramide levels were analyzed by TLC/ELISA, and AA,
DHA, malonyldialdehyde (MDA) and nitrotyrosine (NT3) using TLC followed by
GC/MS. All three CF patients reported lower frequencies of respiratory infections
and an overall improvement of performance status while on lycopene. Decreases
in oxidation parameters, MDA and NT3, were observed in 2/3 CF patients. After
1 month, DHA increased 2−4 fold in 2/3 CF patients. After 3 months, ceramide
increased 5−6 fold in 2/3 patients attaining the normal range seen in HC. In one
CF patient, treatment normalized NT3, AA and ceramide. No adverse effects were
observed during the treatment with lycopene. This pilot study suggests oxidative
stress and lipid defects can be corrected with nutritional supplementation. We
anticipate that the larger cohort of CF patients currently tested will allow a full
assessment of the improvements induced by lycopene.
